id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-343034-dzvo9v01	Chen, Chun-Fan	Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19	2020-04-29		.txt	text/plain	1294	77	52	The pandemic infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is widely increasing the patients affiliated with coronavirus disease 2019 (COVID-19) from last December of 2019. Notably, whether the ACE-related inhibitors or drugs modulated ACE2 activity in affecting the viral activity and disease severity of SARS-CoV-2 is still an open question. In this article, we are focusing on the impact of ACE inhibitors (ACEI) and DPP4 inhibitors used on SARS-CoV-2 activity and discussions about those drugs that may be related to infectious condition of COVID-19 diseases. Severe acute respiratory syndrome coronavirus (SARS-CoV-1) was the first epidemic coronavirus threat infected more than 8000 people with case-fatality rate (CFR) about 11%. Previous experiments had confirmed that angiotensin-converting enzyme 2 (ACE2) is the entry receptor in SARS-CoV-1 and dipeptidyl peptidase-4 (DPP4, also known as CD26) is the entry receptor in MERS-CoV. Among numerous anti-diabetic drugs, DPP4 inhibitors might play an important role during coronavirus infection, including pandemic COVID-19.	./cache/cord-343034-dzvo9v01.txt	./txt/cord-343034-dzvo9v01.txt